This episode is from the European Cancer Congress that took place in Vienna, Austria from September 25-29, 2015.

Prof Tom Powles ECC 2015 Atezolizumab

You will hear leading experts talk about the latest cancer immunotherapy data. Professor Tom Powles (Barts, London) discusses the exciting data presented for renal and bladder cancer.

Dr Martin Reck (Grosshansdorf, near Hamburg) talks about the lung cancer immunotherapy data presented in Vienna and the new checkpoint inhibitor data at the meeting. He offers his perspective on the importance of quality-of-life in clinical decision making, and what role biomakers may play in Europe.

We’ve published commentary and analysis about the latest “Controversies in Lung Cancer Immunotherapy” on Biotech Strategy Blog (subscription required).

Dr Nora Disis (University of Washington, Seattle) takes us through her ovarian cancer poster and offers insights into how we may get checkpoints to work better in tumors that are not hypermutated (like melanoma, renal, bladder) but are immunogenic i.e. able to elicit an immune response.

Photo by © ASCO/Todd Buchanan 2015

Photo by © ASCO/Todd Buchanan 2015

Lung cancer is the No 1 cause of cancer related death in the United States.

Which is why the whole of this episode is devoted to the latest lung cancer data presented at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO) that took place recently in Chicago.

In the podcast you’ll hear from Dr Jack West (pictured right) a medical oncologist at Swedish Medical Center in Seattle and Dr Ross Camidge, Director of Thoracic Oncology at the University of Colorado.

Dr West is the President/Founder of GRACE (Global Resource for Advancing Cancer Education).